{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:57:45Z","timestamp":1765961865507,"version":"3.32.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Open Funds for Shaanxi Provincial Key Laboratory of Infection and Immune Diseases","award":["2022-KFZD-2"],"award-info":[{"award-number":["2022-KFZD-2"]}]},{"DOI":"10.13039\/501100017596","name":"Natural Science Basic Research Program of Shaanxi Province","doi-asserted-by":"publisher","award":["2022JZ-57"],"award-info":[{"award-number":["2022JZ-57"]}],"id":[{"id":"10.13039\/501100017596","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Technology Talent Support Program of Shaanxi Provincial People\u2019s Hospital","award":["2021LJ-01"],"award-info":[{"award-number":["2021LJ-01"]}]},{"name":"Shaanxi Qinchuangyuan traditional Chinese medicine innovation research and development program","award":["2022-QCYZH-004"],"award-info":[{"award-number":["2022-QCYZH-004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-13428-1","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:43:57Z","timestamp":1736325837000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Correlation analysis of DLG5 and PD-L1 expression in triple-negative breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Jingmin","family":"Che","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xusheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuixiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangjun","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"13428_CR1","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.breast.2023.03.003","volume":"69","author":"K Altundag","year":"2023","unstructured":"Altundag K. Indolent triple negative breast cancer patients are more likely to develop late relapse compared to triple negative breast cancer patients with a high proliferation index. Breast. 2023;69:506.","journal-title":"Breast"},{"key":"13428_CR2","doi-asserted-by":"publisher","first-page":"1060308","DOI":"10.3389\/fimmu.2023.1060308","volume":"14","author":"M Khan","year":"2023","unstructured":"Khan M, Du K, Ai M, Wang B, Lin J, Ren A, Chen C, Huang Z, Qiu W, Yuan Y, et al. PD-L1 expression as biomarker of efficacy of PD-1\/PD-L1 checkpoint inhibitors in metastatic triple negative breast cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1060308.","journal-title":"Front Immunol"},{"issue":"4","key":"13428_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"13428_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13058-018-1004-0","volume":"20","author":"MT Barrett","year":"2018","unstructured":"Barrett MT, Lenkiewicz E, Malasi S, Basu A, Yearley JH, Annamalai L, McCullough AE, Kosiorek HE, Narang P, Wilson Sayres MA, et al. The association of genomic lesions and PD-1\/PD-L1 expression in resected triple-negative breast cancers. Breast Cancer Res. 2018;20(1):71.","journal-title":"Breast Cancer Res"},{"key":"13428_CR5","doi-asserted-by":"crossref","unstructured":"Said SS, Ibrahim WN. Breaking barriers: the promise and challenges of immune checkpoint inhibitors in triple-negative breast cancer. Biomedicines. 2024;12(2).","DOI":"10.3390\/biomedicines12020369"},{"issue":"6","key":"13428_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1080\/13543784.2022.2049232","volume":"31","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto E, Losurdo A, Nader-Marta G, Santoro A, Punie K, Barroso R, Popovic L, Solinas C, Kok M, de Azambuja E, et al. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert Opin Investig Drugs. 2022;31(6):567\u201391.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"13428_CR7","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1007\/s11864-023-01087-y","volume":"24","author":"J Dixon-Douglas","year":"2023","unstructured":"Dixon-Douglas J, Loi S. Immunotherapy in Early-Stage Triple-negative breast Cancer: where are we now and where are we headed? Curr Treat Options Oncol. 2023;24(8):1004\u201320.","journal-title":"Curr Treat Options Oncol"},{"key":"13428_CR8","doi-asserted-by":"publisher","first-page":"154676","DOI":"10.1016\/j.prp.2023.154676","volume":"248","author":"S Mirzaei","year":"2023","unstructured":"Mirzaei S, Ranjbar B, Tackallou SH, Aref AR. Hypoxia inducible factor-1alpha (HIF-1alpha) in breast cancer: the crosstalk with oncogenic and onco-suppressor factors in regulation of cancer hallmarks. Pathol Res Pract. 2023;248:154676.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"13428_CR9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.gendis.2023.02.039","volume":"11","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Xing C, Deng Y, Ye C, Peng H. HIF-1alpha signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234\u201351.","journal-title":"Genes Dis"},{"key":"13428_CR10","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036304","volume":"20","author":"Y Li","year":"2021","unstructured":"Li Y, Zhao L, Li XF. Hypoxia and the Tumor Microenvironment. Technol Cancer Res Treat. 2021;20:15330338211036304.","journal-title":"Technol Cancer Res Treat"},{"key":"13428_CR11","doi-asserted-by":"publisher","first-page":"1199105","DOI":"10.3389\/fonc.2023.1199105","volume":"13","author":"N Srivastava","year":"2023","unstructured":"Srivastava N, Usmani SS, Subbarayan R, Saini R, Pandey PK. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens. Front Oncol. 2023;13:1199105.","journal-title":"Front Oncol"},{"issue":"1","key":"13428_CR12","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11033-023-08947-8","volume":"51","author":"FK Chamani","year":"2024","unstructured":"Chamani FK, Etebari A, Hajivalili M, Mosaffa N, Jalali SA. Hypoxia and programmed cell death-ligand 1 expression in the tumor microenvironment: a review of the effects of hypoxia-induced factor-1 on immunotherapy. Mol Biol Rep. 2024;51(1):88.","journal-title":"Mol Biol Rep"},{"key":"13428_CR13","doi-asserted-by":"publisher","first-page":"42125","DOI":"10.1038\/srep42125","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li J, Li P, Wang Y, Liang Z, Jiang Y, Li J, Feng C, Wang R, Chen H, et al. Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo signaling pathway. Sci Rep. 2017;7:42125.","journal-title":"Sci Rep"},{"issue":"3","key":"13428_CR14","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.devcel.2007.07.017","volume":"13","author":"T Nechiporuk","year":"2007","unstructured":"Nechiporuk T, Fernandez TE, Vasioukhin V. Failure of epithelial tube maintenance causes hydrocephalus and renal cysts in Dlg5-\/- mice. Dev Cell. 2007;13(3):338\u201350.","journal-title":"Dev Cell"},{"issue":"24","key":"13428_CR15","doi-asserted-by":"publisher","first-page":"21709","DOI":"10.1074\/jbc.M211004200","volume":"278","author":"M Wakabayashi","year":"2003","unstructured":"Wakabayashi M, Ito T, Mitsushima M, Aizawa S, Ueda K, Amachi T, Kioka N. Interaction of lp-dlg\/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact. J Biol Chem. 2003;278(24):21709\u201314.","journal-title":"J Biol Chem"},{"issue":"9","key":"13428_CR16","first-page":"1611","volume":"128","author":"J Luo","year":"2023","unstructured":"Luo J, Zou H, Guo Y, Tong T, Chen Y, Xiao Y, Pan Y, Li P. The oncogenic roles and clinical implications of YAP\/TAZ in breast cancer. Br J Cancer. 2023;128(9):1611\u201324.","journal-title":"Br J Cancer"},{"issue":"6","key":"13428_CR17","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1158\/0008-5472.CAN-17-3139","volume":"78","author":"HJ van Janse","year":"2018","unstructured":"van Janse HJ, Azad T, Ling M, Hao Y, Snetsinger B, Khanal P, Minassian LM, Graham CH, Rauh MJ, Yang X. The Hippo Pathway Component TAZ promotes Immune Evasion in Human Cancer through PD-L1. Cancer Res. 2018;78(6):1457\u201370.","journal-title":"Cancer Res"},{"issue":"7","key":"13428_CR18","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1158\/1078-0432.CCR-15-1555","volume":"22","author":"YR Liu","year":"2016","unstructured":"Liu YR, Jiang YZ, Xu XE, Hu X, Yu KD, Shao ZM. Comprehensive Transcriptome Profiling reveals Multigene signatures in Triple-negative breast Cancer. Clin Cancer Res. 2016;22(7):1653\u201362.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13428_CR19","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3892\/ijo.2012.1744","volume":"42","author":"M Komatsu","year":"2013","unstructured":"Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto S, et al. Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol. 2013;42(2):478\u2013506.","journal-title":"Int J Oncol"},{"issue":"2","key":"13428_CR20","doi-asserted-by":"publisher","first-page":"e88280","DOI":"10.1371\/journal.pone.0088280","volume":"9","author":"K Kodippili","year":"2014","unstructured":"Kodippili K, Vince L, Shin JH, Yue Y, Morris GE, McIntosh MA, Duan D. Characterization of 65 epitope-specific dystrophin monoclonal antibodies in canine and murine models of duchenne muscular dystrophy by immunostaining and Western blot. PLoS ONE. 2014;9(2):e88280.","journal-title":"PLoS ONE"},{"issue":"12","key":"13428_CR21","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/jnci\/djab108","volume":"113","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Loi S, Adams S, Schmid P, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Winer EP, Kockx MM, et al. PD-L1 immunohistochemistry assay comparison in Atezolizumab plus nab-paclitaxel-treated Advanced Triple-negative breast Cancer. J Natl Cancer Inst. 2021;113(12):1733\u201343.","journal-title":"J Natl Cancer Inst"},{"key":"13428_CR22","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.phrs.2018.08.004","volume":"135","author":"Y Xing","year":"2018","unstructured":"Xing Y, Mi C, Wang Z, Zhang ZH, Li MY, Zuo HX, Wang JY, Jin X, Ma J. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1alpha and STAT3. Pharmacol Res. 2018;135:166\u201380.","journal-title":"Pharmacol Res"},{"key":"13428_CR23","doi-asserted-by":"publisher","first-page":"653212","DOI":"10.3389\/fphar.2021.653212","volume":"12","author":"B He","year":"2021","unstructured":"He B, Zhang W, He J. Fraxinellone has anticancer activity by inducing Osteosarcoma Cell apoptosis via promoting Excessive Autophagy Flux. Front Pharmacol. 2021;12:653212.","journal-title":"Front Pharmacol"},{"key":"13428_CR24","doi-asserted-by":"publisher","first-page":"113416","DOI":"10.1016\/j.biopha.2022.113416","volume":"153","author":"J Shi","year":"2022","unstructured":"Shi J, Sun S, Xing S, Huang C, Huang Y, Wang Q, Xue X, Chen Z, Wang Y, Huang Z. Fraxinellone inhibits progression of glioblastoma via regulating the SIRT3 signaling pathway. Biomed Pharmacother. 2022;153:113416.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"13428_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41416-021-01630-4","volume":"126","author":"J Tutzauer","year":"2022","unstructured":"Tutzauer J, Sjostrom M, Holmberg E, Karlsson P, Killander F, Leeb-Lundberg LMF, Malmstrom P, Nimeus E, Ferno M, Jogi A. Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up. Br J Cancer. 2022;126(8):1145\u201356.","journal-title":"Br J Cancer"},{"issue":"1","key":"13428_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"43","key":"13428_CR27","doi-asserted-by":"publisher","first-page":"e35493","DOI":"10.1097\/MD.0000000000035493","volume":"102","author":"L Liu","year":"2023","unstructured":"Liu L, Bai J, Hu L, Jiang D. Hypoxia-mediated activation of hypoxia-inducible factor-1alpha in triple-negative breast cancer: a review. Med (Baltim). 2023;102(43):e35493.","journal-title":"Med (Baltim)"},{"issue":"1","key":"13428_CR28","doi-asserted-by":"publisher","first-page":"54","DOI":"10.25082\/CCR.2020.01.005","volume":"2","author":"N Mori","year":"2020","unstructured":"Mori N, Mironchik Y, Wildes F, Wu SY, Mori K, Krishnamachary B, Bhujwalla ZM. HIF and COX-2 expression in triple negative breast cancer cells with hypoxia and 5-fluorouracil. Curr Cancer Rep. 2020;2(1):54\u201363.","journal-title":"Curr Cancer Rep"},{"issue":"1","key":"13428_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40659-019-0221-z","volume":"52","author":"NK Rana","year":"2019","unstructured":"Rana NK, Singh P, Koch B. CoCl(2) simulated hypoxia induce cell proliferation and alter the expression pattern of hypoxia associated genes involved in angiogenesis and apoptosis. Biol Res. 2019;52(1):12.","journal-title":"Biol Res"},{"key":"13428_CR30","doi-asserted-by":"crossref","unstructured":"Zhang Y, Tang Y, Tang X, Wang Y, Zhang Z, Yang H. Paclitaxel induces the apoptosis of prostate cancer cells via ROS-mediated HIF-1alpha expression. Molecules. 2022;27(21).","DOI":"10.3390\/molecules27217183"},{"key":"13428_CR31","unstructured":"Zhang XT, Chen RA, Li WS, Han RH, Su11 W, Liu YF, Cai YY, Xiong Y, Wang S. Transcriptomic characterization reveals blood-based molecular signatures of NSCLC patients in response to anti-PD-1 therapy combined with chemotherapy."},{"key":"13428_CR32","doi-asserted-by":"publisher","first-page":"109821","DOI":"10.1016\/j.biopha.2020.109821","volume":"124","author":"S Tan","year":"2020","unstructured":"Tan S, Li D, Zhu X. Cancer immunotherapy: pros, cons and beyond. Biomed Pharmacothera. 2020;124:109821.","journal-title":"Biomed Pharmacotherapy = Biomedecine Pharmacotherapie"},{"issue":"12","key":"13428_CR33","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1007\/s11033-021-06752-9","volume":"48","author":"AR Kumar","year":"2021","unstructured":"Kumar AR, Devan AR, Nair B, Vinod BS, Nath LR. Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Mol Biol Rep. 2021;48(12):8075\u201395.","journal-title":"Mol Biol Rep"},{"issue":"10","key":"13428_CR34","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1080\/14737140.2023.2265059","volume":"23","author":"K Tarekegn","year":"2023","unstructured":"Tarekegn K, Keskinkilic M, Kristoff TJ, Evans ST, Kalinsky K. The role of immune checkpoint inhibition in triple negative breast cancer. Expert Rev Anticancer Ther. 2023;23(10):1095\u2013106.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"13428_CR35","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.tranon.2018.01.011","volume":"11","author":"Z Liu","year":"2018","unstructured":"Liu Z, Li M, Jiang Z, Wang X. A comprehensive immunologic portrait of Triple-negative breast Cancer. Transl Oncol. 2018;11(2):311\u201329.","journal-title":"Transl Oncol"},{"issue":"1","key":"13428_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12964-021-00742-x","volume":"19","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tan J, Miao Y, Zhang Q. The role of PD-L1 in the immune dysfunction that mediates hypoxia-induced multiple organ injury. Cell Commun Signal. 2021;19(1):76.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"13428_CR37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-021-01102-5","volume":"14","author":"XC Ding","year":"2021","unstructured":"Ding XC, Wang LL, Zhang XD, Xu JL, Li PF, Liang H, Zhang XB, Xie L, Zhou ZH, Yang J, et al. The relationship between expression of PD-L1 and HIF-1alpha in glioma cells under hypoxia. J Hematol Oncol. 2021;14(1):92.","journal-title":"J Hematol Oncol"},{"issue":"Pt 4","key":"13428_CR38","doi-asserted-by":"publisher","first-page":"136580","DOI":"10.1016\/j.ijbiomac.2024.136580","volume":"281","author":"X Lu","year":"2024","unstructured":"Lu X, Li L, Lin J, Wu X, Li W, Tan C, Huang J, Pu J. PAARH promotes M2 macrophage polarization and immune evasion of liver cancer cells through VEGF protein. Int J Biol Macromol. 2024;281(Pt 4):136580.","journal-title":"Int J Biol Macromol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13428-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13428-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T21:28:06Z","timestamp":1736371686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13428-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13428"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13428-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the Declaration of Helsinki, this study was approved by the Ethics Committee of Shaanxi Cancer Hospital, ethical approval number: Yilunshen (2024 Ke) No. 11.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}